Annexon, Inc. ANNX
Set alert
At close · Oct 30
After hours · Oct 30, 5:58 PM ET
- YTD
- -19.32%
- 1 year
- +38.23%
- Open
- 4.00
- Prev close
- 4.01
- Mkt cap
- 767.80M
- Vol
- 2.84M
- Avg vol
- 3.14M
- EPS
- -1.13
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.87
- High
- 4.09
- Forward P/E
- -6.48
- Beta
- 1.15
- Short ratio
- 6.15
- Inst. own
- 92.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 5.52
- 200-d avg
- 4.10
- 1y target
- 13.71
News
-
4 days ago benzinga.com
Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event
Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026.…
4 days ago globenewswire.com
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
1 week ago benzinga.com
Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday
Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
-
1 week ago benzinga.com
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25
HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
2 weeks ago globenewswire.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
-
1 month ago benzinga.com
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $15.
1 month ago seekingalpha.com
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash…
1 month ago globenewswire.com
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal…
1 month ago globenewswire.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
2 months ago globenewswire.com
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
2 months ago globenewswire.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
2 months ago seekingalpha.com
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Annexon Q2 Earnings Call Highlights
Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month…
-
2 months ago benzinga.com
Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 17.65 percent increase over losses of $(0.34)…
2 months ago globenewswire.com
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA…
-
2 months ago benzinga.com
Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy
Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…
2 months ago globenewswire.com
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple…
-
2 months ago benzinga.com
Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved…
2 months ago globenewswire.com
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies
-
3 months ago benzinga.com
Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…
3 months ago globenewswire.com
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration
-
3 months ago benzinga.com
Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3
Citizens analyst Jonathan Wolleben initiates coverage on Annexon (NASDAQ:ANNX) with a Market Underperform rating and announces Price Target of $3.
3 months ago globenewswire.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
-
3 months ago benzinga.com
Needham Maintains Buy on Annexon, Raises Price Target to $25
Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $11 to $25.
-
3 months ago benzinga.com
Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people…
3 months ago globenewswire.com
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
3 months ago seekingalpha.com
Annexon: Perfect Complement To A Speculative Biotech Portfolio
Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome (GBS). Tanruprubart achieved highly significant Phase 3…
4 months ago globenewswire.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at…
4 months ago seekingalpha.com
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4 months ago marketbeat.com
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
Annexon NASDAQ: ANNX executives used a Goldman Sachs Healthcare Conference session to outline the company's upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the…
5 months ago marketbeat.com
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across the company's complement-focused pipeline during a session at the Jefferies Conference,…
-
5 months ago benzinga.com
Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7
Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral rating and announces Price Target of $7.
-
5 months ago benzinga.com
Annexon Q1 EPS $(0.23) Beats $(0.29) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 37.84 percent increase over losses of $(0.37) per…
7 months ago benzinga.com
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
-
7 months ago benzinga.com
Annexon Q4 EPS $(0.28) Beats $(0.32) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.32) by 11.11 percent. This is a 15.15 percent increase over losses of $(0.33) per…
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
2 years ago benzinga.com
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
-
2 years ago benzinga.com
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24…
-
2 years ago benzinga.com
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 221 companies hit new 52-week lows.
-
3 years ago benzinga.com
Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR.
-
4 years ago benzinga.com
79 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 466 companies hit new 52-week lows.